-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 21, the official website of CDE revealed that the listing application of Fuhong Henlius "slulimumab injection" is planned to be included in the priority review and approval (acceptance number has not yet been announced), for use in cases that have failed, unresectable, or transferred after standard treatment High degree of microsatellite instability-high (MSI-H) solid tumors.
According to the clinical progress disclosed by Fuhong Henlius before, struzumab should be its PD-1 monoclonal antibody HLX10.
On March 28 this year, Henlius announced its PD-1 monoclonal antibody HLX10 for unresectable or metastatic highly microsatellite instability (MSI-H) or mismatch repair defect (dMMR) that has failed standard treatments.
The study is a single-arm, open, multi-center, phase 2 clinical trial designed to evaluate the efficacy, safety and tolerability of HLX10 in patients with unresectable or metastatic MSI-H solid tumors who have failed standard treatments Yes, clinical research results show that HLX10 has good efficacy and safety in this type of indication.
HLX10 is an innovative anti-PD-1 monoclonal antibody independently developed by Henlius.
HLX10 clinical trial launch (Insight)
From the Insight database (http://db.
The domestic PD-1 competition has now become fierce.
Domestic PD-1 competition (only the first 20 companies are intercepted)